Drug
Peginterferon Alfa-2b
Drug Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | Cytokine Modulators |
| Group | Cytokine Modulators |
| Mechanism of Action | Interferon modulator |
| Half-life | ~40 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Data on this page refer exclusively to patients treated with
Peginterferon Alfa-2b combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Cytokine Modulators group page.